{
    "clinical_study": {
        "@rank": "14771", 
        "arm_group": {
            "arm_group_label": "carcinoma, Paclitaxel onkovis (Paclitaxel)", 
            "description": "treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer."
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this observational study with Paclitaxel is to determine the number of\n      treatment cycles and the quantity of Paclitaxel onkovis needed therefore under the special\n      circumstance of ambulant chemotherapy.\n\n      onkovis aims an economical utilization of the chemotherapeutics.The provision with adapted\n      packaging sizes as to decrease the excess quantity to be discarded follows also this\n      objective.\n\n      Secondary objectives are the survey of the side effects of Paclitaxel onkovis in comparison\n      to Docetaxel. To this purpose, data regarding co medications and adverse events are also\n      collected."
        }, 
        "brief_title": "A Non Interventional Study With Paclitaxel Onkovis (Paclitaxel) Utilized for the Treatment of Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Indication for Paclitaxel according to the SmPC and treating physician\n\n        Exclusion Criteria:\n\n          -  according to the Paclitaxel SmPC"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients treated in practices, clinics, hospitals"
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668108", 
            "org_study_id": "ONKOPAC 01"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "carcinoma", 
            "breast cancer", 
            "non-small cell lung cancer", 
            "ovarial cancer", 
            "ambulant chemotherapy", 
            "treatment cycles", 
            "Paclitaxel", 
            "Paclitaxel onkovis", 
            "Quantity of Paclitaxel", 
            "Packaging Sizes"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brandenburg", 
                        "country": "Germany", 
                        "zip": "14770"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chemnitz", 
                        "country": "Germany", 
                        "zip": "09117"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fchlhausen", 
                        "country": "Germany", 
                        "zip": "99974"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plauen", 
                        "country": "Germany", 
                        "zip": "08525"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer.", 
        "overall_contact": {
            "email": "info@akp-freiburg.de", 
            "last_name": "K.-U. Seiler, PD Dr. med.", 
            "phone": "+49(0)761479400"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the quantity of Paclitaxel onkovis needed pro treatment cycle", 
            "measure": "the quantity of Paclitaxel onkovis needed pro treatment cycle", 
            "safety_issue": "No", 
            "time_frame": "the time the participants will be followed depends on the number of treatment cycles; that means the time frame may extend up to 24 weeks (8 cycles)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668108"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The number and kind of adverse events during and after the intra-venous application of Paclitaxel will be assessed, documented and compared to those of Docetaxel.", 
            "measure": "adverse events during and after treatment in comparison to Docetaxel onkovis", 
            "safety_issue": "Yes", 
            "time_frame": "up to 24 weeks (8 cycles)"
        }, 
        "source": "Onkovis GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "AKP Freiburg GmbH (Clinical Research Organization)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Onkovis GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}